Literature DB >> 9039387

Targeted hepatitis B vaccination--a cost effective immunisation strategy for the UK?

J R Williams1, D J Nokes, R M Anderson.   

Abstract

OBJECTIVE: To compare the potential cost effectiveness of vaccination against hepatitis B virus (HBV) targeted at genitourinary clinic (GU) attendees with that of universal infant vaccination.
DESIGN: A mathematical model of sexual and perinatal transmission of HBV was used to compare the effectiveness among heterosexual and homosexual populations of programmes of mass infant vaccination and targeted immunisation of genitourinary medicine (GU) clinic attendees. Each was applied to 90% of the eligible population with differing assumptions about rates of compliance and seroconversion - problems of delivery (obtaining high compliance) was considered a significant drawback of targeted vaccination. Observed relationships between GU clinic attendance and sex partner change rates for heterosexuals and for homosexuals were used to define the rates of vaccination uptake within sexual activity risk groups.
SETTING: England and Wales.
RESULTS: Model results showed that for heterosexuals universal infant vaccination became more effective than clinic based vaccination only approximately 40 years after the start of the programme and that the predicted cost effectiveness of GU clinic vaccination was greater at all times. For homosexuals, clinic vaccination was always more effective over the time frame considered, but by 50 years if it were carried out without prior screening it had become appreciably less cost effective than a mass infant programme. With prior screening in GU clinics this cost effectiveness deficit was only marginal.
CONCLUSIONS: Targeted vaccination might have a much greater potential than is realised at present, particularly if it were possible to improve compliance of clinic attendees. A fuller comparison between mass infant and targeted vaccination must await the specific inclusion in the model of other risk groups such as intravenous drug users. An important determinant of the relative merits of the two approaches is the relationship between rates of attendance and of changing sexual partners. Further research on this is required.

Entities:  

Mesh:

Year:  1996        PMID: 9039387      PMCID: PMC1060385          DOI: 10.1136/jech.50.6.667

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  18 in total

1.  Chronic hepatitis B in male and female children of HBsAg carrier mothers.

Authors:  S M Wheeley; M J Tarlow; E H Boxall
Journal:  J Hepatol       Date:  1989-03       Impact factor: 25.083

2.  Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males.

Authors:  U Laukamm-Josten; G von Laer; H Feldmeier; U Bienzle; A Uy; R Thomssen; I Guggenmoos-Holzmann
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

Review 3.  Herd immunity: history, theory, practice.

Authors:  P E Fine
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

4.  Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine.

Authors:  F E André
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

5.  WHO strategy for the global elimination of new cases of hepatitis B.

Authors:  Y Ghendon
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

6.  Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital.

Authors:  M G Brook; A M Lever; D Kelly; D Rutter; R S Trompeter; P Griffiths; H C Thomas
Journal:  Q J Med       Date:  1989-04

7.  The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes.

Authors:  J R Williams; D J Nokes; G F Medley; R M Anderson
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

8.  Transmission of HBsAg from mother to infant in four ethnic groups.

Authors:  A Derso; E H Boxall; M J Tarlow; T H Flewett
Journal:  Br Med J       Date:  1978-04-15

9.  Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.

Authors:  P Mangtani; A J Hall; C E Normand
Journal:  J Epidemiol Community Health       Date:  1995-06       Impact factor: 3.710

10.  Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic.

Authors:  N Bhatti; R J Gilson; M Beecham; P Williams; M P Matthews; R S Tedder; I V Weller
Journal:  BMJ       Date:  1991-07-13
View more
  3 in total

Review 1.  Should universal hepatitis B immunisation be introduced in the UK?

Authors:  P English
Journal:  Arch Dis Child       Date:  2006-04       Impact factor: 3.791

2.  Economic evaluation of delivering hepatitis B vaccine to injection drug users.

Authors:  Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer
Journal:  Am J Prev Med       Date:  2008-07       Impact factor: 5.043

3.  Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage.

Authors:  R J Gilson; A de Ruiter; J Waite; E Ross; C Loveday; D R Howell; R S Tedder; I V Weller
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.